Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 1/20 | 0.36 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.36 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.36 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.36 |
| ▸ | GRIN2D | O15399 | 4/20 | 0.33 |
| ▸ | GRIN3B | O60391 | 4/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.33 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.33 |
| ▸ | GRIN2C | Q14957 | 4/20 | 0.33 |
| ▸ | GRIN3A | Q8TCU5 | 4/20 | 0.33 |
| ▸ | EIF4A3 | P38919 | 1/20 | 0.33 |
| ▸ | TYMP | P19971 | 3/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | PNP | P00491 | 1/20 | 0.32 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29388927 | 1.00 | IDH1 (0.36) | IDH1CSNK2A2CSNK2BCSNK2A1GRIN2D | |
| SCHEMBL24717492 | 0.84 | ALDH1A1 (0.35) | CSNK2A1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL25988754 | 0.83 | IDH1 (0.39) | IDH1CSNK2A2CSNK2BCSNK2A1GRIN2D | |
| SCHEMBL25814975 | 0.83 | IDH1 (0.39) | IDH1CSNK2A2CSNK2BCSNK2A1GRIN2D | |
| SCHEMBL25601009 | 0.81 | IDH1 (0.38) | IDH1CSNK2A2CSNK2BCSNK2A1GRIN2D | |
| SCHEMBL23540965 | 0.81 | AR (0.41) | IDH1CSNK2A2CSNK2BCSNK2A1GRIN2D | |
| SCHEMBL29947950 | 0.81 | AR (0.41) | IDH1CSNK2A2CSNK2BCSNK2A1GRIN2D | |
| SCHEMBL24791176 | 0.80 | GRIN2D (0.38) | IDH1CSNK2A2CSNK2BCSNK2A1GRIN2D | |
| SCHEMBL23539934 | 0.80 | IDH1 (0.36) | IDH1CSNK2A2CSNK2BCSNK2A1GRIN2D | |
| SCHEMBL21379214 | 0.80 | IDH1 (0.36) | IDH1CSNK2A2CSNK2BCSNK2A1GRIN2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630547-B2 | RAS protein degraders, pharmaceutical compositions thereof, and their therapeutic applications | BIOTHERYX, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-12552783-B2 | Modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-RE50490-E1 | Substituted quinazoline compounds and methods of use thereof | ARAXES PHARMA LLC (US) | 2025-07-15 | — | — | US | disclosed |
| US-20250171464-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2025-05-29 | — | — | US | disclosed |
| US-12275745-B2 | Therapeutic compounds and methods of use | GENENTECH, INC. (US) | 2025-04-15 | — | — | US | disclosed |
| US-20250074881-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2025-03-06 | — | — | US | disclosed |
| US-12234244-B2 | Substituted piperazines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2025-02-25 | — | — | US | disclosed |
| US-20250059163-A1 | FUSED RING COMPOUNDS | GENENTECH INC (US) | 2025-02-20 | — | — | US | disclosed |
| EP-4483881-A2 | FUSED RING COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2025-01-01 | — | — | EP | disclosed |
| US-20240352028-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2024-10-24 | — | — | US | disclosed |
| WO-2016164675-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC (US) | 2016-10-13 | — | — | WO | disclosed |
| US-20160297774-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2016-10-13 | — | — | US | disclosed |
| WO-2016164675-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC (US) | 2016-10-13 | — | — | WO | disclosed |
| US-20160297774-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2016-10-13 | — | — | US | disclosed |
| EP-3055290-A1 | INHIBITORS OF KRAS G12C | Araxes Pharma LLC (US) | 2016-08-17 | — | — | EP | disclosed |
| US-20150239900-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2015-08-27 | — | — | US | disclosed |
| US-20150239900-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2015-08-27 | — | — | US | disclosed |
| US-20150239900-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2015-08-27 | — | — | US | disclosed |
| WO-2015054572-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2015-04-16 | — | — | WO | disclosed |
| WO-2015054572-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2015-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630547-B2 | RAS protein degraders, pharmaceutical compositions thereof, and their therapeutic applications | KRAS, RSU1, NRAS | IDH1 2475/4885CSNK2A2 257/4885CSNK2B 321/4885 |
| US-20250074881-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | VHL, TP53, MCL1 | IDH1 1179/4885CSNK2A2 2333/4885CSNK2B 2656/4885 |
| US-12234244-B2 | Substituted piperazines as inhibitors of KRAS G12C | KRAS, NRAS, HRAS | IDH1 415/4885CSNK2A2 1061/4885CSNK2B 678/4885 |
| US-20250171464-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | VHL, TP53, MCL1 | IDH1 1179/4885CSNK2A2 2333/4885CSNK2B 2656/4885 |
| US-20250059163-A1 | FUSED RING COMPOUNDS | KRAS, NRAS, HRAS | IDH1 289/4885CSNK2A2 216/4885CSNK2B 187/4885 |
| US-20160297774-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | IDH1 82/4885CSNK2A2 542/4885CSNK2B 214/4885 |
| US-20240352028-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | IDH1 181/4885CSNK2A2 449/4885CSNK2B 253/4885 |
| US-20150239900-A1 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | IDH1 353/4885CSNK2A2 857/4885CSNK2B 384/4885 |
| US-12275745-B2 | Therapeutic compounds and methods of use | VHL, TP53, MCL1 | IDH1 1179/4885CSNK2A2 2333/4885CSNK2B 2656/4885 |
| US-12552783-B2 | Modulators of proteolysis and associated methods of use | CRBN, ADRM1, MDM2 | IDH1 1039/4885CSNK2A2 144/4885CSNK2B 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.